A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans - PubMed
Affiliations
- PMID: 8682970
Review
A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans
H M Gloster Jr et al. J Am Acad Dermatol. 1996 Jul.
Abstract
Background: There is growing evidence that Mohs micrographic surgery (MMS) is the treatment of choice for dermatofibrosarcoma protuberans (DFSP).
Objective: This study retrospectively compared the recurrence rates of DFSP after MMS with those after wide surgical excision; results at the Mayo Clinic and in the world literature were evaluated. In addition, preoperative tumor sizes and postoperative defect sizes after MMS were compared to determine whether MMS conserved more normal tissue than wide surgical excision.
Methods: The medical records of 84 patients with DFSP who had been treated at the Mayo Clinic were reviewed. They were categorized into two treatment groups: MMS and surgical excision.
Results: Fifteen patients with DFSP who underwent MMS had follow-up data available; one of these patients had local recurrence (recurrence rate, 6.6%; average duration of follow-up, 40 months). Thirty-nine patients had wide excision; four of these patients had local recurrences and one had pulmonary metastases (recurrence rate, 10%; average duration of follow-up, 36 months). A review of the world literature revealed neither local recurrences nor metastases in the 11 studies in which DFSP was treated with MMS. Overall, including our results, the average recurrence rate of DFSP after MMS was 0.6% (range, 0% to 6.6%) and the total recurrence rate was 1.6% (1 of 64). Including our series, DFSP was treated with wide excision in 15 studies; the average recurrence rate was 18% (range, 0% to 60%) and the total recurrence rate was 20% (100 of 489). In eight published studies, DFSP was surgically resected with undefined or conservative excisional margins; the average recurrence rate was 43% (range, 26% to 60%) and the total recurrence rate was 44% (140 of 317). A surgical margin of 2.5 cm to deep fascia was required for complete clearance of all tumors treated with MMS. Twenty-two percent of tumors were removed with a 0.5 cm margin, 50% with a 1.0 cm margin, 67% with a 1.5 cm margin, and 89% with a 2.0 cm margin.
Conclusion: On the basis of our results and data compiled from the literature, MMS may be the treatment of choice for DFSP because of its high cure rate and maximal conservation of tissue.
Similar articles
-
Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB. Snow SN, et al. Cancer. 2004 Jul 1;101(1):28-38. doi: 10.1002/cncr.20316. Cancer. 2004. PMID: 15221986
-
Ratner D, Thomas CO, Johnson TM, Sondak VK, Hamilton TA, Nelson BR, Swanson NA, Garcia C, Clark RE, Grande DJ. Ratner D, et al. J Am Acad Dermatol. 1997 Oct;37(4):600-13. doi: 10.1016/s0190-9622(97)70179-8. J Am Acad Dermatol. 1997. PMID: 9344201
-
Lowe GC, Onajin O, Baum CL, Otley CC, Arpey CJ, Roenigk RK, Brewer JD. Lowe GC, et al. Dermatol Surg. 2017 Jan;43(1):98-106. doi: 10.1097/DSS.0000000000000910. Dermatol Surg. 2017. PMID: 27749444
-
Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery.
Paradisi A, Abeni D, Rusciani A, Cigna E, Wolter M, Scuderi N, Rusciani L, Kaufmann R, Podda M. Paradisi A, et al. Cancer Treat Rev. 2008 Dec;34(8):728-36. doi: 10.1016/j.ctrv.2008.06.002. Epub 2008 Aug 5. Cancer Treat Rev. 2008. PMID: 18684568 Review.
-
Malan M, Xuejingzi W, Quan SJ. Malan M, et al. Pan Afr Med J. 2019 Aug 13;33:297. doi: 10.11604/pamj.2019.33.297.17692. eCollection 2019. Pan Afr Med J. 2019. PMID: 31692830 Free PMC article. Review.
Cited by
-
Dermatofibrosarcoma Protuberans: Insights into a Rare Soft Tissue Tumor.
Al Barwani AS, Taif S, Al Mazrouai RA, Al Muzahmi KS, Alrawi A. Al Barwani AS, et al. J Clin Imaging Sci. 2016 Apr 29;6:16. doi: 10.4103/2156-7514.181492. eCollection 2016. J Clin Imaging Sci. 2016. PMID: 27195182 Free PMC article. Review.
-
Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy.
Fields RC, Hameed M, Qin LX, Moraco N, Jia X, Maki RG, Singer S, Brennan MF. Fields RC, et al. Ann Surg Oncol. 2011 Feb;18(2):328-36. doi: 10.1245/s10434-010-1316-5. Epub 2010 Sep 16. Ann Surg Oncol. 2011. PMID: 20844969 Free PMC article. Clinical Trial.
-
Dermatofibrosarcoma Protuberans.
Acosta AE, Vélez CS. Acosta AE, et al. Curr Treat Options Oncol. 2017 Aug 10;18(9):56. doi: 10.1007/s11864-017-0498-5. Curr Treat Options Oncol. 2017. PMID: 28795284 Review.
-
Imatinib in the treatment of solid tumours.
Duffaud F, Le Cesne A. Duffaud F, et al. Target Oncol. 2009 Jan;4(1):45-56. doi: 10.1007/s11523-008-0101-x. Epub 2009 Jan 27. Target Oncol. 2009. PMID: 19343301 Review.
-
Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans.
Rutkowski P, Wozniak A, Switaj T. Rutkowski P, et al. Sarcoma. 2011;2011:959132. doi: 10.1155/2011/959132. Epub 2011 Mar 30. Sarcoma. 2011. PMID: 21559214 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical